Flecainide may be prescribed off-label for maintaining sinus rhythm after cardioversion in atrial fibrillation patients who have no structural heart disease. This use is not approved by the MHRA and requires specialist supervision and regular ECG monitoring.
The strategy allows patients with intermittent supraventricular tachycardia to carry a single flecainide tablet for emergency self-treatment, taking it at the onset of symptoms. It is only appropriate after a cardiologist confirms suitability and instructs on dosing.
Flecainide is a pure sodium-channel blocker (class IC) with rapid onset and relatively short half-life, whereas amiodarone has multiple electrophysiologic actions (class I-IV) and a very long half-life, leading to different side-effect profiles and monitoring requirements.
In the UK, the 100 mg generic flecainide tablet is typically round, white, and imprinted with “F-100” (branding may vary by manufacturer). Patients should verify the imprint with the pharmacy label.
Flecainide does not interfere with standard laboratory assays for lipid or glucose levels, so routine blood work for these parameters can be performed without special timing.
Aviation medical standards often prohibit class IC anti-arrhythmics due to the risk of sudden arrhythmias. Pilots should disclose flecainide use to their aviation medical examiner; continuation may be restricted.
Grapefruit juice can inhibit CYP3A4 but flecainide is primarily metabolised by CYP2D6, so a significant interaction is unlikely. Nonetheless, patients should maintain consistent dietary habits and discuss any concerns with their prescriber.
Maintain the same dosing interval (e.g., every 12 hours) regardless of local time, adjusting the clock rather than the interval. If travel disrupts the schedule, contact a healthcare professional for guidance.
If the bottle remains tightly sealed and stored at room temperature, the tablet retains potency until the printed expiration date. No specific “once opened” limit applies, but moisture exposure should be avoided.
Flecainide is available as a generic prescription on the NHS, which generally reduces patient cost compared with brand-named equivalents. Patients can discuss eligibility for NHS prescription prepayment certificates or prescription pre-pay schemes with their pharmacist.
Flecainide (acetate) is a class IC anti-arrhythmic agent used to control abnormal heart rhythms. It is marketed as a generic medication and is available in a 100 mg oral pill form. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) classifies flecainide as a prescription-only medicine (POM).
Flecainide blocks fast sodium channels in cardiac myocytes. By reducing the influx of sodium during phase 0 of the cardiac action potential, it slows the rapid upstroke of depolarisation. This results in:
The drug’s effect begins within 30 minutes of oral ingestion, peaks at 2-3 hours, and its half-life is roughly 20 hours in patients with normal renal function. Flecainide is metabolised primarily by the liver (CYP2D6) and excreted unchanged in the urine.
Flecainide is approved in the UK for the treatment of:
It may be used as a “pill-in-the-pocket” strategy for occasional PSVT episodes, provided a cardiologist has confirmed suitability.
Some clinicians prescribe flecainide for atrial fibrillation (AF) after cardioversion, especially in patients without underlying heart disease. This use is not approved by the MHRA and should only occur under specialist supervision, with careful monitoring for pro-arrhythmic risk.
Disclaimer: Off-label use requires individualized risk assessment and ongoing cardiac monitoring.
Absolute contraindications
Relative contraindications
Special populations
These effects are often transient and may improve with dose titration.
Any sudden chest pain, palpitations, fainting, or unexplained shortness of breath warrants immediate medical attention.
Patients should provide a full medication list-including over-the-counter drugs and herbal supplements-to their prescriber.
This article provides educational information about flecainide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
